Pascal Sonto, CEO of British-based Astra Zencea

AstraZeneca began producing Oxford’s Covid-19 vaccine 2bn doses to be ready by September

Pascal Sonto, CEO of British-based Astra Zencea
Pascal Sonto, CEO of British-based AstraZeneca
Coronavirus vaccine still at testing stage
Coronavirus vaccine still at testing stage

AstraZeneca is starting the production of English-based Oxford University’s Covid-19 vaccine in UK, Switzerland, India and Norway.

Oxford University’s Covid-19 vaccine is oe of he most promising vaccine candidates across the world. The vaccine is currently in its advanced stage of human trials

Pascal Sonto, CEO said “ We’ve to have it ready for use by the time we have the results. If the vaccine’s ongoing human trials are proven successful by September”. AstraZeneca will mass produce over 2 billion does worldwide.